Randomised, Double-blind, 52-wk, Parallel-grp, Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Diabetic Patients With Moderate Proteinuria.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Atorvastatin (Primary) ; Rosuvastatin (Primary)
- Indications Hypercholesterolaemia
- Focus Pharmacodynamics
- Acronyms PLANET-I
- Sponsors AstraZeneca; AstraZeneca AB
- 25 Aug 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jan 2008 The expected final data collection date for the primary endpoint was 1 Dec 2007 as reported by ClinicalTrials.gov.